The European commission has licensed a new, potentially lifesaving drug to treat cystic fibrosis, meaning it will be available on the NHS to many who have the condition. The drug, Kaftrio, is produced by Vertex Pharmaceuticals and contains three key ingredients: tezacaftor, ivacaftor and elexacaftor. Clinical trials have shown Kaftrio can increase lung function by between 10% to 14% in people with cystic fibrosis, depending on their genetic makeup, and can improve quality of life. Another 300 people in England with cystic fibrosis but with rare mutations will benefit from other Vertex pharmaceutical drugs secured in the deal. It’s such an incredible and special moment for so many people with cystic fibrosis,” she said.

Source: The Guardian August 21, 2020 17:40 UTC